Stockreport

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Biomea Fusion, Inc.  (BMEA) 
PDF Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patient [Read more]